The BCL2L11 Deletion Polymorphism Is Not Associated With Imatinib Resistance in Chronic Myeloid Leukemia Patients: Meta Analysis

Oncotarget - United States
doi 10.18632/oncotarget.21154
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Imatinib Does Not Impair Specific Antitumor T-Cell Immunity in Patients With Chronic Myeloid Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2005English

Prognostic Factors Associated With a Stable MR4.5 Achievement in Chronic Myeloid Leukemia Patients Treated With Imatinib

Oncotarget
Oncology
2017English

Polycomb Genes Are Associated With Response to Imatinib in Chronic Myeloid Leukemia

Epigenomics
Cancer ResearchGenetics
2015English

Micro-Rna Response to Imatinib Mesylate in Patients With Chronic Myeloid Leukemia

Haematologica
Hematology
2010English

Imatinib and Plasmacytoid Dendritic Cell Function in Patients With Chronic Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2004English

Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients

2012English

Gene Expression Signature of Primary Imatinib-Resistant Chronic Myeloid Leukemia Patients

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2006English

Telomere Length Shortening Is Associated With Treatment-Free Remission in Chronic Myeloid Leukemia Patients

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2016English

Pancreatic Enzyme Elevation in Chronic Myeloid Leukemia Patients Treated With Nilotinib After Imatinib Failure

Haematologica
Hematology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy